Both a GHRH antagonist and agonist reduced anxiety and depression-like behavior in mice, while decreasing brain inflammation, boosting serotonin and norepinephrine, and activating antioxidant pathways.
Both agonist & antagonist workedParadoxically, both GHRH agonist MR-409 and antagonist MIA-690 produced anxiolytic and antidepressant effects in mice
What the researchers found
Both MIA-690 (antagonist) and MR-409 (agonist) produced anxiolytic and antidepressant-like effects, increased monoamine neurotransmitters, decreased NF-κB/TNF-α/IL-6, and increased Nrf2 expression in mouse prefrontal cortex, with MIA-690 showing higher anti-inflammatory efficacy.
Why it matters
GHRH analogues were developed as anti-cancer agents, but these brain effects suggest they could have unexpected therapeutic potential for neuropsychiatric conditions involving inflammation and oxidative stress.
The numbers in context
5 mcg/day for 4 weeks; increased NE and serotonin; decreased NF-kB, TNF-α, IL-6; increased Nrf2; MIA-690 stronger anti-inflammatory
How the study worked
Ex vivo: tested both compounds on LPS-treated mouse prefrontal cortex specimens for anti-inflammatory and antioxidant effects. In vivo: chronic treatment of mice followed by behavioral testing for anxiety and depression, with brain tissue analysis for neurotransmitters, inflammatory markers, and gene expression.
Who was studied
Mice (ex vivo prefrontal cortex and chronic in vivo treatment)
What this study cannot tell us
Mouse study — behavioral tests may not translate to human psychiatric conditions. Mechanism of anxiolytic/antidepressant action not fully defined. Surprising that both agonist and antagonist produce similar behavioral effects. Sample sizes not reported.
How to read the evidence
Preliminary — mouse behavioral and molecular data suggesting novel brain effects of GHRH analogues, with no human psychiatric data.
When this study was published
Published in 2020; the neuropsychiatric potential of GHRH analogues remains largely unexplored clinically.
The bigger picture
This study adds to growing evidence that growth hormone-related peptides have significant neuromodulatory effects beyond endocrine function, potentially opening new treatment avenues for mood disorders with inflammatory components.
Questions still open
- Why do both GHRH agonist and antagonist produce similar behavioral effects despite opposing endocrine actions?
- Could GHRH analogues be developed specifically for neuropsychiatric indications?
- Do these compounds affect other brain regions involved in mood regulation beyond the prefrontal cortex?
Common questions
What is GHRH and what are its analogues used for?
How might these compounds help with anxiety and depression?
Read the original research
Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.
Scientific reports, 10(1), 732
Citation
Recinella, Lucia; Chiavaroli, Annalisa; Orlando, Giustino; Ferrante, Claudio; Marconi, Guya Diletta; Gesmundo, Iacopo; Granata, Riccarda; Cai, Renzhi; Sha, Wei; Schally, Andrew V; Brunetti, Luigi; Leone, Sheila. (2020). Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.. Scientific reports, 10(1), 732. https://doi.org/10.1038/s41598-019-57292-z